Cite
Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2 -Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.
MLA
Meijer, Titia G., et al. “Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2 -Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.” Cancers, vol. 16, no. 4, Feb. 2024, p. 741. EBSCOhost, https://doi.org/10.3390/cancers16040741.
APA
Meijer, T. G., Martens, J. W. M., Prager-van der Smissen, W. J. C., Verkaik, N. S., Beaufort, C. M., van Herk, S., Robert-Finestra, T., Hoogenboezem, R. M., Ruigrok-Ritstier, K., Paul, M. W., Gribnau, J., Bindels, E. M. J., Kanaar, R., Jager, A., van Gent, D. C., & Hollestelle, A. (2024). Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2 -Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient. Cancers, 16(4), 741. https://doi.org/10.3390/cancers16040741
Chicago
Meijer, Titia G., John W. M. Martens, Wendy J. C. Prager-van der Smissen, Nicole S. Verkaik, Corine M. Beaufort, Stanley van Herk, Teresa Robert-Finestra, et al. 2024. “Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2 -Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.” Cancers 16 (4): 741. doi:10.3390/cancers16040741.